Side-by-side comparison
Bristol-Myers Squibb vs Eli Lilly and
As of Sep 25, 2026, P/E is 13.8x for Bristol-Myers Squibb vs 39.7x for Eli Lilly and; P/S is 2.6x for Bristol-Myers Squibb vs 14.0x for Eli Lilly and; revenue growth is 3.1% for Bristol-Myers Squibb vs 49.6% for Eli Lilly and; net margin is 18.9% for Bristol-Myers Squibb vs 33.5% for Eli Lilly and.
Key metrics
| Metric | BMY | LLY |
|---|---|---|
| Price | $62.86 | $1,183.46 |
| Market cap | $128.41B | $1.11T |
| P/E | 13.8x (#1) | 39.7x (#2) |
| P/S | 2.6x (#1) | 14.0x (#2) |
| Revenue growth | 3.1% (#2) | 49.6% (#1) |
| Operating margin | — | — |
| Net margin | 18.9% (#2) | 33.5% (#1) |
| Debt / equity | 1.89 (#2) | 1.41 (#1) |
| 1-year return | +42.5% (#2) | +63.3% (#1) |
| Research score | 71/100 (#1) | 69/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Bristol-Myers Squibb Company (BMY) — Drug Manufacturers—General
- Eli Lilly and Company (LLY) — Drug Manufacturers—General